Charlotta Nilsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charlotta Nilsson has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Dag Ursing
Department of Endocrinology, Skane University Hospital, Lund, Sweden
4 shared publicationsHelena Strevens
Institution of Clinical Sciences, Lund University, Lund, Sweden
4 shared publicationsMona Landin-Olsson
Department of Endocrinology, Institution of Clinical Sciences, Skåne University Hospital, Lund University, Sweden
3 shared publicationsMona Landin‐Olsson
Department of Endocrinology, Skane University Hospital, Lund, Sweden
3 shared publications- Jonatan Dereke
Department of Clinical Sciences, Diabetes Research Laboratory, Lund University, Lund, Sweden
2 shared publications - Magnus Hillman
Center for Teaching and Learning, Faculty of Medicine, Lund University, Lund, Sweden
2 shared publications
Latest Publications
- 15 April 2025
- Published by SAGE Publications in Acta Radiologica
A validation of ultrasound as a diagnostic tool for the detection of testicular torsion
Background: Testicular torsion (TT) is a scrotal emergency that needs urgent detection for successful treatment. Purpose: To investigate the diagnostic value of acute ultrasound and the possibility of more effective detection. Material and Methods: This retrospective study included patients assessed with ultrasound for suspicion of TT between 2019 and 2023. Registration of parameters included symptoms, durations, ultrasound conclusions, and surgical outcome. Ultrasound assessment included inspection of the spermatic cord and testicular color Doppler signal. Sensitivity and specificity were presented with 95% confidence intervals (CIs) and symptoms with odds ratios (ORs). Results: A total of 387 patients were included. Surgical exploration (SE) was carried out in 40 patients. TT was surgically confirmed in 23 patients. No missed cases of TT were detected. Spermatic cord rotation ≥180° showed a sensitivity of 100% (95% CI=86–100), specificity of 65% (95% CI=41–83), positive predictive value (PPV) of 79%, and negative predictive value (NPV) of 100%. Absent or reduced testicular color Doppler signal showed a sensitivity of 57% (95% CI=37–74), specificity of 77% (95% CI=53–90), PPV of 76%, and NPV of 57%. Sudden onset of pain (OR=9.44, 95% CI=2.10–42.35), earlier similar episodes (OR=6.71, 95% CI=2.27–19.89), and abdominal pain (OR=14.70, 95% CI=3.25–66.51) showed significant association with TT. Conclusion: Ultrasound, with focus on the spermatic cord, is reliable as a tool for the detection of TT. SE might be justified when cord rotation is ≥180°. These results can be used to develop and validate ultrasound guidelines for fast detection.
- 15 April 2025
- Published by SAGE Publications in Acta Radiologica
A validation of ultrasound as a diagnostic tool for the detection of testicular torsion
Background: Testicular torsion (TT) is a scrotal emergency that needs urgent detection for successful treatment. Purpose: To investigate the diagnostic value of acute ultrasound and the possibility of more effective detection. Material and Methods: This retrospective study included patients assessed with ultrasound for suspicion of TT between 2019 and 2023. Registration of parameters included symptoms, durations, ultrasound conclusions, and surgical outcome. Ultrasound assessment included inspection of the spermatic cord and testicular color Doppler signal. Sensitivity and specificity were presented with 95% confidence intervals (CIs) and symptoms with odds ratios (ORs). Results: A total of 387 patients were included. Surgical exploration (SE) was carried out in 40 patients. TT was surgically confirmed in 23 patients. No missed cases of TT were detected. Spermatic cord rotation ≥180° showed a sensitivity of 100% (95% CI=86–100), specificity of 65% (95% CI=41–83), positive predictive value (PPV) of 79%, and negative predictive value (NPV) of 100%. Absent or reduced testicular color Doppler signal showed a sensitivity of 57% (95% CI=37–74), specificity of 77% (95% CI=53–90), PPV of 76%, and NPV of 57%. Sudden onset of pain (OR=9.44, 95% CI=2.10–42.35), earlier similar episodes (OR=6.71, 95% CI=2.27–19.89), and abdominal pain (OR=14.70, 95% CI=3.25–66.51) showed significant association with TT. Conclusion: Ultrasound, with focus on the spermatic cord, is reliable as a tool for the detection of TT. SE might be justified when cord rotation is ≥180°. These results can be used to develop and validate ultrasound guidelines for fast detection.
- Open Access
- 18 April 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (1) , 1251-1257
Cystatin C as an adjunct to HbA1c may prove useful in predicting the development of diabetic complications in children and adolescents with type 1 diabetes
Purpose: Complications from diabetes mellitus can occur over time and although glycosylated hemoglobin (HbA1c) is a good biomarker for glycaemic control, other factors also contribute to the development of complications in type 1 diabetes. More markers able to identify the risk of complications are needed. This study aimed to investigate plasma levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 in children and adolescents with different duration of type 1 diabetes and possible correlation to HbA1c to identify potential biomarkers of future complication development. Methods: Patients (n = 244, 0–18 years) with type 1 diabetes, at Helsingborg’s Hospital, Sweden, were included in this study. Circulating levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 were investigated in plasma using automated ELISA with the ELLA™ system and standardised controls. Results: Cystatin C levels were elevated in patients with diabetes duration longer than 5 years (P < 0.001). HbA1c and Cystatin C levels were inversely correlated for all participants (rs = − 0.23, CI95: −0.35-−0.10; P < 0.001). A stepwise multiple regression analysis showed that HbA1c (P < 0.001) and Cystatin C (P = 0.03) were associated to the duration of diabetes at sampling while MMP-9, lipocalin-2, and FGF21 did not reach statistical significance. Conclusion: In conclusion, Cystatin C levels were higher in patients with diabetes duration longer than 5 years, and inverse correlation was found between HbA1c and Cystatin C levels as well as duration of diabetes. Cystatin C may prove useful as an adjunct to HbA1c in predicting eventual development of diabetic complications.
- 18 April 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (1) , 1251-1257
Open AccessCystatin C as an adjunct to HbA1c may prove useful in predicting the development of diabetic complications in children and adolescents with type 1 diabetes
Purpose: Complications from diabetes mellitus can occur over time and although glycosylated hemoglobin (HbA1c) is a good biomarker for glycaemic control, other factors also contribute to the development of complications in type 1 diabetes. More markers able to identify the risk of complications are needed. This study aimed to investigate plasma levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 in children and adolescents with different duration of type 1 diabetes and possible correlation to HbA1c to identify potential biomarkers of future complication development. Methods: Patients (n = 244, 0–18 years) with type 1 diabetes, at Helsingborg’s Hospital, Sweden, were included in this study. Circulating levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 were investigated in plasma using automated ELISA with the ELLA™ system and standardised controls. Results: Cystatin C levels were elevated in patients with diabetes duration longer than 5 years (P < 0.001). HbA1c and Cystatin C levels were inversely correlated for all participants (rs = − 0.23, CI95: −0.35-−0.10; P < 0.001). A stepwise multiple regression analysis showed that HbA1c (P < 0.001) and Cystatin C (P = 0.03) were associated to the duration of diabetes at sampling while MMP-9, lipocalin-2, and FGF21 did not reach statistical significance. Conclusion: In conclusion, Cystatin C levels were higher in patients with diabetes duration longer than 5 years, and inverse correlation was found between HbA1c and Cystatin C levels as well as duration of diabetes. Cystatin C may prove useful as an adjunct to HbA1c in predicting eventual development of diabetic complications.
- Open Access
- 7 July 2022
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 21 (2) , 1427-1432
HbA1c levels and circulating inflammatory proteins at onset of type 1 diabetes in children and adolescents
Purpose: Type 1 diabetes is an autoimmune disease that often develops during childhood. Complications such as retinopathy often occur during the course of the disease. Studies to identify possible predictors of complications in type 1 diabetes are needed; in particular markers able to identify risk of complications long before they occur. The first aim of this study was to investigate plasma levels of sCD163, sST2 and Gal-3 at diagnosis of type 1 diabetes in children and adolescents. The second aim was to study their correlation to HbA1c in this study cohort. Methods: Patients (n = 242, 0–18 years) with type 1 diabetes, at Helsingborg’s Hospital were included in this study and circulating levels of sCD163, sST2 and Gal-3 were investigated in plasma using commercially available DuoSet ELISA and supplementary ancillary kit. Results: Circulating sCD163 was significantly higher at diagnosis compared to after diagnosis (666 ± 318ng/ml and 505 ± 223ng/ml respectively; p < 0.001). Also sST2 was significantly higher (18.2 [12.7–25.6] ng/ml respectively 9.1 [6.3–13.5] ng/ml (p < 0.001), but Gal-3 levels did not differ from onset of diabetes to after diagnosis. HbA1c was shown to correlate to sCD163 (rs=0.36; p < 0.001), sST2 (rs=0.22; p = 0.016) and Gal-3 (rs=0.2; p = 0.020) in patients with a diabetes duration < 5 years. Conclusions: sCD163 levels increased in patients with recent-onset type 1 diabetes and the levels increased with higher HbA1c. Patients included in this study will be followed annually until the eventual development of diabetic complications, while continuously studying circulating levels of inflammatory proteins such as sCD163.
- 7 July 2022
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 21 (2) , 1427-1432
Open AccessHbA1c levels and circulating inflammatory proteins at onset of type 1 diabetes in children and adolescents
Purpose: Type 1 diabetes is an autoimmune disease that often develops during childhood. Complications such as retinopathy often occur during the course of the disease. Studies to identify possible predictors of complications in type 1 diabetes are needed; in particular markers able to identify risk of complications long before they occur. The first aim of this study was to investigate plasma levels of sCD163, sST2 and Gal-3 at diagnosis of type 1 diabetes in children and adolescents. The second aim was to study their correlation to HbA1c in this study cohort. Methods: Patients (n = 242, 0–18 years) with type 1 diabetes, at Helsingborg’s Hospital were included in this study and circulating levels of sCD163, sST2 and Gal-3 were investigated in plasma using commercially available DuoSet ELISA and supplementary ancillary kit. Results: Circulating sCD163 was significantly higher at diagnosis compared to after diagnosis (666 ± 318ng/ml and 505 ± 223ng/ml respectively; p < 0.001). Also sST2 was significantly higher (18.2 [12.7–25.6] ng/ml respectively 9.1 [6.3–13.5] ng/ml (p < 0.001), but Gal-3 levels did not differ from onset of diabetes to after diagnosis. HbA1c was shown to correlate to sCD163 (rs=0.36; p < 0.001), sST2 (rs=0.22; p = 0.016) and Gal-3 (rs=0.2; p = 0.020) in patients with a diabetes duration < 5 years. Conclusions: sCD163 levels increased in patients with recent-onset type 1 diabetes and the levels increased with higher HbA1c. Patients included in this study will be followed annually until the eventual development of diabetic complications, while continuously studying circulating levels of inflammatory proteins such as sCD163.
- Open Access
- 1 March 2021
- Published by Wiley in Practical Diabetes
- Vol. 38 (2) , 13-19
Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes
The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra‐long effect. However, there are few published studies in children and adolescents.The first aim was to compare HbA1c levels in children and adolescents who received degludec from onset, to age/gender matched controls with other basal insulins. The second aim was to investigate HbA1c and total basal insulin dose, in patients who switched to insulin degludec from another basal insulin.Patients (n=251, 0–21 years) with type 1 diabetes, at Helsingborg Hospital, were divided into groups depending on insulin treatment. Data regarding basal insulin and HbA1c values were collected from medical records retrospectively.No significant differences in HbA1c levels were found between patients receiving degludec compared to age/gender matched controls (n=22) up to 12 months from onset. In patients who switched to degludec with HbA1c ≥70mmol/mol (n=38), median HbA1c levels decreased from 75 (70–130) to 74 (39–99; p=0.0143) after three months and to 70.5 (55–108; p=0.0290) after six months. For patients who switched from detemir to degludec (n=54) median daily basal insulin dosage reduced from 23.5 units to 22 units after six months treatment with degludec (p=0.0001). The same significance was not found for glargine.In our study, degludec has shown to be as effective in lowering HbA1c levels as other basal insulins in children and adolescents with type 1 diabetes. Degludec might be especially useful for patients with a poor metabolic control. However, further long‐term studies are needed. Copyright © 2021 John Wiley & Sons.
- 1 March 2021
- Published by Wiley in Practical Diabetes
- Vol. 38 (2) , 13-19
Open AccessEvaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes
The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra‐long effect. However, there are few published studies in children and adolescents.The first aim was to compare HbA1c levels in children and adolescents who received degludec from onset, to age/gender matched controls with other basal insulins. The second aim was to investigate HbA1c and total basal insulin dose, in patients who switched to insulin degludec from another basal insulin.Patients (n=251, 0–21 years) with type 1 diabetes, at Helsingborg Hospital, were divided into groups depending on insulin treatment. Data regarding basal insulin and HbA1c values were collected from medical records retrospectively.No significant differences in HbA1c levels were found between patients receiving degludec compared to age/gender matched controls (n=22) up to 12 months from onset. In patients who switched to degludec with HbA1c ≥70mmol/mol (n=38), median HbA1c levels decreased from 75 (70–130) to 74 (39–99; p=0.0143) after three months and to 70.5 (55–108; p=0.0290) after six months. For patients who switched from detemir to degludec (n=54) median daily basal insulin dosage reduced from 23.5 units to 22 units after six months treatment with degludec (p=0.0001). The same significance was not found for glargine.In our study, degludec has shown to be as effective in lowering HbA1c levels as other basal insulins in children and adolescents with type 1 diabetes. Degludec might be especially useful for patients with a poor metabolic control. However, further long‐term studies are needed. Copyright © 2021 John Wiley & Sons.
- Open Access
- 7 April 2020
- Published by Knowledge E DMCC in Journal of Family & Reproductive Health
- Vol. 13 (4) , 176-180
Weight Development in Children After Gastric Bypass Surgery
Objective: More and more young obese women get pregnant after undergoing gastric bypass surgery (GBP) but little is known about weight development in their offspring. The first aim of this study was to investigate weight development of children whose mothers have undergone GBP before pregnancy and compare them to age specific reference values in Sweden. Second aim was to study the frequency of small for gestational age (SGA) in this population. Materials and methods: Weight of offspring (38 male and 28 female) where the mother had undergone GBP before pregnancy were studied from birth up to 18 months of age and compared to age-specific reference values in Sweden. Results: The boys to mothers who had undergone GBP before pregnancy weighed more than Swedish reference values at 6 months, 8.44 ± 1.18 kilogram (kg) (n = 35) vs. 7.98 ± 0.81 kg (n = 1388; p = 0.001), and less at 18 months, 11.54 ± 0.93 kg (n = 19) vs. 12.27 ± 1.19 kg (n = 862; p < 0.001). The girls to mothers who had undergone GBP before pregnancy weighed more than Swedish reference values at 6 months, 7.84 ± 1.00 kg (n = 28) vs. 7.50 ± 0.77 kg (n = 1375; p = 0.020). Frequency of SGA was 3.0%. Conclusion: No clear pattern was found concerning the short-term weight development of the children. However, studies with larger material and more follow up time must be performed.
- 7 April 2020
- Published by Knowledge E DMCC in Journal of Family & Reproductive Health
- Vol. 13 (4) , 176-180
Open AccessWeight Development in Children After Gastric Bypass Surgery
Objective: More and more young obese women get pregnant after undergoing gastric bypass surgery (GBP) but little is known about weight development in their offspring. The first aim of this study was to investigate weight development of children whose mothers have undergone GBP before pregnancy and compare them to age specific reference values in Sweden. Second aim was to study the frequency of small for gestational age (SGA) in this population. Materials and methods: Weight of offspring (38 male and 28 female) where the mother had undergone GBP before pregnancy were studied from birth up to 18 months of age and compared to age-specific reference values in Sweden. Results: The boys to mothers who had undergone GBP before pregnancy weighed more than Swedish reference values at 6 months, 8.44 ± 1.18 kilogram (kg) (n = 35) vs. 7.98 ± 0.81 kg (n = 1388; p = 0.001), and less at 18 months, 11.54 ± 0.93 kg (n = 19) vs. 12.27 ± 1.19 kg (n = 862; p < 0.001). The girls to mothers who had undergone GBP before pregnancy weighed more than Swedish reference values at 6 months, 7.84 ± 1.00 kg (n = 28) vs. 7.50 ± 0.77 kg (n = 1375; p = 0.020). Frequency of SGA was 3.0%. Conclusion: No clear pattern was found concerning the short-term weight development of the children. However, studies with larger material and more follow up time must be performed.
- 26 October 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (3) , 333-340
Pregnancy outcome in women with gestational diabetes – A longitudinal study of changes in demography and treatment modalities
Introduction: Gestational diabetes is on the rise and demographics are changing in many countries due to increased migration. Simultaneously, the treatment of gestational diabetes in our clinic has shifted towards metformin with substantially less insulin treatment. The aim was to study the impact of these changes on metabolic control and pregnancy outcome by comparing women diagnosed with gestational diabetes during 2012‐2013 and 2016‐2017.Material and methods: Our universal Oral Glucose Tolerance Test screening program for gestational diabetes diagnosed 199 women with singleton pregnancies during 2012‐2013 and 203 during 2016‐2017. Treatment and achieved metabolic control in the two different time periods were compared. Pregnancy outcome data related to gestational diabetes were retrieved from case notes and compared between the different time periods.Results: When comparing results from 2016‐2017 with 2012‐2013 there was no difference in maternal weight or weight gain. There was a higher frequency of heredity (52.6 vs 35.4%; P = 0.001) and non‐Scandinavian ethnicity (46.5 vs 33.8%; P = 0.011).The frequency of smoking during pregnancy was significantly lower (2.6 vs 7.7%; P = 0.023) There was an improved metabolic control as measured by median glucose in 2016‐2017 compared with 2012‐2013 (5.8 vs 6.2 mmol/L; P < 0.001). Insulin was less frequently used in 2016‐2017 than in 2012‐2013 (32.5 vs 44.7%; P = 0.012). There was a significant increase in the use of metformin (14.8 vs 0%; P < 0.001). There were no differences regarding the frequency of large‐for‐gestational‐age infants (8.2% vs 7.3%; P = 0.762) or macrosomia (16.3 vs 15.1%; P = 0.745), median birthweight (3510 vs 3521; P = 0.879), frequency of cesarean section (28.1 vs 27.8%; P = 0.951) or Apgar scores at 10 minutes (10 [3‐10] vs 10 [7‐10]; P = 0.290).Conclusions: In an increasing but changing population of gestational diabetes women in our region, with more hereditary and non‐Scandinavian origins, but with fewer smokers, metabolic control has improved with maintained favorable pregnancy outcomes, with more frequent use of metformin and substantially less use of insulin treatment.
- 26 October 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (3) , 333-340
Pregnancy outcome in women with gestational diabetes – A longitudinal study of changes in demography and treatment modalities
Introduction: Gestational diabetes is on the rise and demographics are changing in many countries due to increased migration. Simultaneously, the treatment of gestational diabetes in our clinic has shifted towards metformin with substantially less insulin treatment. The aim was to study the impact of these changes on metabolic control and pregnancy outcome by comparing women diagnosed with gestational diabetes during 2012‐2013 and 2016‐2017.Material and methods: Our universal Oral Glucose Tolerance Test screening program for gestational diabetes diagnosed 199 women with singleton pregnancies during 2012‐2013 and 203 during 2016‐2017. Treatment and achieved metabolic control in the two different time periods were compared. Pregnancy outcome data related to gestational diabetes were retrieved from case notes and compared between the different time periods.Results: When comparing results from 2016‐2017 with 2012‐2013 there was no difference in maternal weight or weight gain. There was a higher frequency of heredity (52.6 vs 35.4%; P = 0.001) and non‐Scandinavian ethnicity (46.5 vs 33.8%; P = 0.011).The frequency of smoking during pregnancy was significantly lower (2.6 vs 7.7%; P = 0.023) There was an improved metabolic control as measured by median glucose in 2016‐2017 compared with 2012‐2013 (5.8 vs 6.2 mmol/L; P < 0.001). Insulin was less frequently used in 2016‐2017 than in 2012‐2013 (32.5 vs 44.7%; P = 0.012). There was a significant increase in the use of metformin (14.8 vs 0%; P < 0.001). There were no differences regarding the frequency of large‐for‐gestational‐age infants (8.2% vs 7.3%; P = 0.762) or macrosomia (16.3 vs 15.1%; P = 0.745), median birthweight (3510 vs 3521; P = 0.879), frequency of cesarean section (28.1 vs 27.8%; P = 0.951) or Apgar scores at 10 minutes (10 [3‐10] vs 10 [7‐10]; P = 0.290).Conclusions: In an increasing but changing population of gestational diabetes women in our region, with more hereditary and non‐Scandinavian origins, but with fewer smokers, metabolic control has improved with maintained favorable pregnancy outcomes, with more frequent use of metformin and substantially less use of insulin treatment.
- 1 March 2018
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 31 (4) , 369-374
HbA1clevels in children with type 1 diabetes and correlation to diabetic retinopathy
Background: Type 1 diabetes mellitus (T1D) is a metabolic disease causing hyperglycemia due to β-cell destruction. Despite adequate treatment, complications such as diabetic retinopathy (DR) are common. The first aim was to investigate if acute onset of type 1 diabetes differed between those who had developed retinopathy and who had not after 15 years from diagnosis. The second aim was to investigate if mean glycosylated hemoglobin (HbA1c) levels affect the time to development of DR. Methods: The medical records of all children and adolescents diagnosed with type 1 diabetes during 1993–2001 in our area in Sweden were studied retrospectively and the mean HbA1c each year until the development of retinopathy was investigated. In total 72 patients were included and the follow-up time was between 15 and 23 years. Gender, p-glucose, age and HbA1c at diagnosis were analyzed for possible correlations to years to retinopathy. Results: HbA1c was significantly higher among those who had developed DR after 15 years from diagnosis, 98±9.2 (n=25) vs. 86±9.2 (n=46; p=0.025). A negative correlation was found between age at diagnosis and years to DR (rs=−0.376; p=0.026). Mean HbA1c levels at years 6–10 after diabetes diagnosis correlated significantly (rs=−0.354, p=0.037) to years until retinopathy. Mean HbA1c levels at years 1–15 after diabetes diagnosis were significantly higher at years 2–3 and years 5–8 for those who had developed retinopathy after 15 years from diagnosis. Conclusions: Higher HbA1c levels shortened the time to development of retinopathy. It is therefore important to keep HbA1c as close to normal as possible.
- 1 March 2018
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 31 (4) , 369-374
HbA1clevels in children with type 1 diabetes and correlation to diabetic retinopathy
Background: Type 1 diabetes mellitus (T1D) is a metabolic disease causing hyperglycemia due to β-cell destruction. Despite adequate treatment, complications such as diabetic retinopathy (DR) are common. The first aim was to investigate if acute onset of type 1 diabetes differed between those who had developed retinopathy and who had not after 15 years from diagnosis. The second aim was to investigate if mean glycosylated hemoglobin (HbA1c) levels affect the time to development of DR. Methods: The medical records of all children and adolescents diagnosed with type 1 diabetes during 1993–2001 in our area in Sweden were studied retrospectively and the mean HbA1c each year until the development of retinopathy was investigated. In total 72 patients were included and the follow-up time was between 15 and 23 years. Gender, p-glucose, age and HbA1c at diagnosis were analyzed for possible correlations to years to retinopathy. Results: HbA1c was significantly higher among those who had developed DR after 15 years from diagnosis, 98±9.2 (n=25) vs. 86±9.2 (n=46; p=0.025). A negative correlation was found between age at diagnosis and years to DR (rs=−0.376; p=0.026). Mean HbA1c levels at years 6–10 after diabetes diagnosis correlated significantly (rs=−0.354, p=0.037) to years until retinopathy. Mean HbA1c levels at years 1–15 after diabetes diagnosis were significantly higher at years 2–3 and years 5–8 for those who had developed retinopathy after 15 years from diagnosis. Conclusions: Higher HbA1c levels shortened the time to development of retinopathy. It is therefore important to keep HbA1c as close to normal as possible.
- 1 October 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 193, 132-135
Outcomes of women with gestational diabetes mellitus in Sweden
- 1 October 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 193, 132-135
Outcomes of women with gestational diabetes mellitus in Sweden
- 14 July 2015
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 94 (10) , 1090-1094
Towards normalized birthweight in gestational diabetes mellitus
The objective was to describe pregnancy outcomes in gestational diabetes mellitus (GDM) in comparison with general population in Sweden
- 14 July 2015
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 94 (10) , 1090-1094
Towards normalized birthweight in gestational diabetes mellitus
The objective was to describe pregnancy outcomes in gestational diabetes mellitus (GDM) in comparison with general population in Sweden